30/12/2024
Discover New Treatment Options for Obstructive Sleep Apnea with Greys Health
At Greys Health, we stay at the forefront of medical advancements to provide innovative care. The recent FDA approval of Zepbound (tirzepatide) marks a groundbreaking development for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Zepbound, combined with a reduced-calorie diet and increased physical activity, offers hope for OSA patients by reducing body weight and improving airway obstruction. In clinical trials, Zepbound significantly lowered apnea and hypopnea events while helping many achieve remission or mild OSA symptoms.
While Zepbound represents a major step forward, it’s essential to understand its potential risks. Side effects can include nausea, diarrhea, and injection site reactions, among others. It is contraindicated in patients with a history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2.
At Greys Health, we prioritize your safety and well-being. If you’re struggling with OSA or have questions about this new treatment, contact us today to explore personalized solutions that fit your health journey.
Visit us at www.GreysHealth.com to learn more or schedule a consultation.
